Bringing the very best science and medicine to our best equine friends
May 2017

Kindred Biosciences to Present Data from Six Studies at the 2017 American College of Veterinary Internal Medicine Conference

San Francisco, CA (May 30, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will be presenting data from six studies at the 2017 American College of Veterinary Internal Medicine (ACVIM) conference in National Harbor, MD, held June 8-10, 2017.  The Company will be sharing effectiveness and safety data from its Mirataz™ (mirtazapine transdermal ointment) and Zimeta™ (dipyrone injection) development programs and sponsoring scientific sessions. In addition, KindredBio will be sponsoring five Scientific Sessions at the conference. “We are proud that all six of the abstracts we …

Continue Reading

Kindred Biosciences to Present at 7th Annual LD Micro Invitational

San Francisco, CA (May 24, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Co-Founder and COO, will be presenting and hosting one-on-one investor meetings at the 7thAnnual LD Micro Invitational in Los Angeles, CA on Tuesday, June 6, 2017 at 1:30 PM PST. The conference will be held at the Luxe Sunset Bel Air Hotel. Following the presentation, the slide deck will be available for 30 days on the Company’s website: https://kindredbio.com/investor-relations/events. About Kindred Biosciences Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and …

Continue Reading

Kindred Biosciences Announces First Quarter 2017 Financial Results

San Francisco, CA (May 3, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2017 and provided updates on its programs. “The first quarter of 2017 has been extremely successful for KindredBio. We continue to expect approval of Mirataz and Zimeta IV by second half of 2017, if the FDA review continues to proceed well. We have been receiving very positive feedback from key opinion leaders and other veterinarians about the product profiles of the products, and look forward to …

Continue Reading

Kindred Biosciences Announces Initiation of Enrollment in Pivotal Effectiveness Trial of Zimeta Oral for the Control of Fever in Horses

San Francisco, CA (May 1, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the first patient has been enrolled in the pivotal effectiveness trial evaluating its novel, oral formulation of Zimeta™ (dipyrone oral gel) for the control of fever in horses. “We are very pleased to announce initiation of enrollment in our pivotal effectiveness trial for Zimeta Oral. This milestone brings us one step closer to bringing this innovative oral gel to owners and veterinarians and reflects continued progress of our rich pipeline,” stated Richard Chin, M.D., …

Continue Reading